Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Conclave 2025, Vikrant Shrotriya, Managing Director of Novo Nordisk India, said that a weight loss drug is not a magic pill.

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...

Stifel downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 700, down from DKK 780. Novo is “no longer the same stock that ...

Novo Nordisk said Wednesday it will sell Wegovy at lower prices to uninsured patients and to patients whose insurance doesn’t ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Tirzepatide is part of a class of drugs known as dual GIP/GLP-1 receptor agonists. These act on hormones involved in the ...

Novo Nordisk owns two of them ... for when it gets FDA approval to sell VK2735 in pill form. Viking told investors that this agreement "provides Viking with sufficient long-term supply of both ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...